Hansa Biopharma AB (publ) announced that the current chair Ulf Wiinberg has chosen to not stand for re-election.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
48.84 SEK | +4.81% |
|
+16.73% | +86.41% |
May. 31 | Hansa Biopharma Finalizes Patient Randomization for Use of Imlifidase inKidney Transplantation Trial | MT |
May. 31 | Hansa Biopharma Completes Randomization in Pivotal Phase 3 Us Confides Trial | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+86.41% | 300M | |
+23.13% | 52.73B | |
+37.49% | 39B | |
-8.73% | 38.52B | |
+28.09% | 30.38B | |
-12.26% | 26.39B | |
+10.57% | 26.08B | |
+45.05% | 14.15B | |
+32.23% | 12.6B | |
-6.56% | 11.51B |
- Stock Market
- Equities
- HNSA Stock
- News Hansa Biopharma AB
- Hansa Biopharma AB's Current Chair Ulf Wiinberg Has Chosen to Not Stand for Re-Election